LLY trades against a final fair-value range of $1,025.31-$1,935.83, with the midpoint set by the accepted valuation synthesis rather than earlier draft model outputs. Fair value range: low $1025, high $1936, with mid-point at $1466.
Stock analysis
Eli Lilly and CompanyLLY Eli Lilly and Company fair value $1,466–$1,936
Engelse bron wordt weergegeven terwijl we vertalen
Dit rapport is nog niet vertaald. Vernieuw over een paar minuten zodra de vertaalwachtrij is bijgewerkt.
§1 Samenvatting
Composite fair value $1,466 with high case $1,936.
Implied upside of 50.3% to fair value.
Moat 9/10 · confidence 88/100 · Hyper-growth.
Trades below fair value with a meaningful cushion to the midpoint.
Fair value
$1,466
Margin of safety
+33.5%
Confidence
88/100
Moat
9/10
Educational analysis only — not financial advice. Always do your own due diligence.
$974.96Price
FV $1,465.75
High $1,935.83
LLY trades against a final fair-value range of $1,025.31-$1,935.83, with the midpoint set by the accepted valuation synthesis rather than earlier draft model outputs.
Intangible assets
Extensive patent protection on core GLP-1 portfolio.
Switching costs
High clinical inertia and patient reliance on established dosing.
Bull thesis
The $1,465.75 fair value bridges the benchmark gap by correctly weighting forward EPS to capture explicit pipeline momentum.
§2 Berenscenario
A severe margin compression event driven by aggressive competitor pricing, early regulatory intervention in obesity treatments, and slower-than-expected capacity expansion. This scenario forces reliance on slower-growth legacy assets.
Hoe deze these kan breken
Severe Pricing Regulation
· Medium
Medicare aggressively negotiates GLP-1 pricing, capping margins and triggering cascading price cuts across commercial channels.
FV impact
Down to Floor Model ($741.88)
Trigger
1-3 Years
Long-Term Safety Signal
· Low
Unforeseen long-term adverse cardiovascular or gastrointestinal events associated with chronic Mounjaro/Zepbound use surface.
FV impact
Severe multiple contraction
Trigger
3-5 Years
Oral Competitor Domination
· Low
Next-generation oral obesity treatments from competitors demonstrate superior efficacy and tolerability, obliterating the injectable market.
FV impact
Reduces long-term growth to low single digits
Trigger
5+ Years
Vroege waarschuwingssignalen om te volgen
Metriek
Huidig
Trigger-drempel
Sequential decline in new prescriptions for Zepbound.
Monitor
Deterioration versus the report thesis
Gross margin falling below 70% due to persistent scale-up costs.
Monitor
Deterioration versus the report thesis
CapEx-to-Revenue ratio remaining above 15% without commensurate revenue inflection.
Monitor
Deterioration versus the report thesis
PBMs securing steeper rebates, compressing net realized pricing.
Monitor
Deterioration versus the report thesis
Delay in oral GLP-1 pipeline readouts.
Monitor
Deterioration versus the report thesis
§3 Financiële historie
Winst-en-verliesrekening — laatste zes perioden
Post
T−0
T−1
T−2
T−3
T−4
CAGR
Periode
2021-12-31
2022-12-31
2023-12-31
2024-12-31
2025-12-31
Trend
Omzet
$28.32B
$28.54B
$34.12B
$45.04B
$65.18B
+23.2%
Brutowinst
$21.01B
$21.91B
$27.04B
$36.63B
$54.13B
+26.7%
Bedrijfsresultaat
$6.36B
$8.28B
$10.33B
$17.04B
$29.70B
+47.0%
Nettowinst
$5.58B
$6.24B
$5.24B
$10.59B
$20.64B
+38.7%
WPA (verwaterd)
$6.14
$6.57
$5.80
$11.71
$22.95
+39.0%
EBITDA
$7.90B
$8.66B
$11.85B
$18.81B
$31.69B
+41.5%
R&D
$7.90B
$7.19B
$9.31B
$10.99B
$13.34B
+14.0%
VAA
$6.43B
$6.44B
$7.40B
$8.59B
$11.09B
+14.6%
Kwaliteitsscores
Piotroski F-score
7 / 9
0–9 kwaliteitscomposiet
Altman Z-score
7.39
Faillissementsrisico (>3 veilig)
Beneish M-score
-1.85
Risico op winstmanipulatie
OCF / Nettowinst
0.82×
>1 wijst op hoge winstkwaliteit
Drempel boekhoudkwaliteit
Pass
Sector-aangepaste drempel
ROIC
34.0%
Rendement op geïnvesteerd kapitaal
Sectie 3
Numbers analysis
Kasstroom
Cash-flow quality is reflected in the OCF / net income, accounting-quality, and ROIC rows above.
Kapitaalallocatie
Capital allocation should be evaluated against reinvestment needs, balance-sheet strength, and shareholder returns.
Individuele abonnees — vanaf §411 extra secties
Lees de volledige analyse — 11 extra secties.
Competitive moat, industry cycle, peer comparison, intrinsic valuation, sensitivity, scenarios, earnings decision tree, position management, investor perspectives, scorecard, and final recommendation.
Based on our latest independent analysis, LLY looks meaningfully undervalued. The current price is $975 versus a composite fair-value midpoint of $1466 (range $1025–$1936), which implies roughly 50.3% upside to the midpoint.
Our composite fair-value range for LLY is $1025–$1936, with a midpoint of $1466. The range is triangulated across multiple valuation models (discounted earnings, forward earnings scenarios, peer multiples, and where applicable owner earnings or reverse DCF) and weighted by reliability for Eli Lilly and Company's archetype.
Our current rating for LLY is Strong Buy with a confidence score of 88/100. LLY is rated Strong Buy at $974.96 versus the reconciled fair value midpoint of $1,465.75, implying +50.34% upside/downside. Confidence is separately disclosed at 88/100. This is independent research for educational purposes, not personalized investment advice.
The top risks our latest report flags for Eli Lilly and Company are: Severe Pricing Regulation; Long-Term Safety Signal; Oral Competitor Domination. The single biggest risk is Severe Pricing Regulation: Medicare aggressively negotiates GLP-1 pricing, capping margins and triggering cascading price cuts across commercial channels.
Our current rating for LLY is Strong Buy, issued with a confidence score of 88/100 and a moat score of 9/10. The rating reflects the composite fair-value range ($1025–$1936) versus the current price of $975.
Eli Lilly and Company is classified as a hyper-growth stock. Archetype determines how every downstream parameter — discount rate, terminal growth, deceleration curve, terminal multiple, scenario probability weights, scorecard weights, and which valuation models are prioritized — is calibrated for LLY.
